0001209191-20-005794.txt : 20200131
0001209191-20-005794.hdr.sgml : 20200131
20200131165850
ACCESSION NUMBER: 0001209191-20-005794
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200129
FILED AS OF DATE: 20200131
DATE AS OF CHANGE: 20200131
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Richardson Joshua
CENTRAL INDEX KEY: 0001793762
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37490
FILM NUMBER: 20565767
MAIL ADDRESS:
STREET 1: C/O LONGITUDE CAPITAL
STREET 2: 2740 SAND HILL ROAD, 2ND FLOOR
CITY: MENLO PARK
STATE: CA
ZIP: 94025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sierra Oncology, Inc.
CENTRAL INDEX KEY: 0001290149
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2150 ? 885 WEST GEORGIA STREET
CITY: VANCOUVER
STATE: A1
ZIP: V6C 3E8
BUSINESS PHONE: 604-558-6536
MAIL ADDRESS:
STREET 1: 2150 ? 885 WEST GEORGIA STREET
CITY: VANCOUVER
STATE: A1
ZIP: V6C 3E8
FORMER COMPANY:
FORMER CONFORMED NAME: ProNAi Therapeutics Inc
DATE OF NAME CHANGE: 20040513
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-01-29
0
0001290149
Sierra Oncology, Inc.
SRRA
0001793762
Richardson Joshua
C/O SIERRA ONCOLOGY, INC.
2150 - 885 WEST GEORGIA STREET
VANCOUVER
A1
V6C 3E8
BRITISH COLUMBIA, CANADA
1
0
1
0
Common Stock
2020-01-29
4
C
0
1477320
0.00
A
1477320
I
By Longitude Venture Partners III, L.P.
Series A Convertible Voting Preferred Stock
2020-01-29
4
C
0
19500
D
Common Stock
1477320
0
I
By Longitude Venture Partners III, L.P.
On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the "Reverse Split") was effected. These securities reflect the Reverse Split.
Each share of Series A Convertible Voting Preferred Stock (the "Series A Preferred Stock") converted into 75.76 shares of the Issuer's Common Stock for no additional consideration, as adjusted for the Reverse Split, automatically upon the 5th trading date following the Issuer's announcement of receiving stockholder approval for the first reverse stock split of the Issuer following November 13, 2019. The Series A Preferred Stock has no expiration date.
Longitude Capital Partners III, LLC ("LCP III") is the general partner of Longitude Venture Partners III, L.P. ("LVP III") and may be deemed to have voting, investment and dispositive power with respect to such securities. Patrick G. Enright, Juliet Tammenoms Bakker and the Reporting Person (a member of the Issuer's board of directors), are each members of LCP III and may be deemed to share voting, investment and dispositive power over such securities. Mr. Enright and Ms. Tammenoms Bakker are the managing members of LCP III. Each of LCP III, Mr. Enright, Ms. Tammenoms Bakker and the Reporting Person disclaim beneficial ownership over such securities except to the extent of their respective pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
Consists of 19,500 shares of Series A Preferred Stock held by LVP III which are convertible into an aggregate of 1,477,320 shares of Common Stock, as adjusted for the Reverse Split.
/s/ Sukhi Jagpal as attorney-in-fact for Joshua Richardson
2020-01-31